ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

ClinicalTrials.gov ID: NCT04514653

Public ClinicalTrials.gov record NCT04514653. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via One or Two Suprachoroidal Space (SCS) Injections in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)

Study identification

NCT ID
NCT04514653
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
146 participants

Conditions and interventions

Interventions

  • ABBV-RGX-314 Dose 1 Genetic
  • ABBV-RGX-314 Dose 2 Genetic
  • ABBV-RGX-314 Dose 3 Genetic
  • ABBV-RGX-314 Dose 4 Genetic
  • Local Steroid Drug
  • Ranibizumab Biological
  • Topical Steroid Drug

Genetic · Drug · Biological

Eligibility (public fields only)

Age range
50 Years to 89 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 24, 2020
Primary completion
Jul 31, 2026
Completion
Jan 31, 2027
Last update posted
Feb 26, 2026

2020 – 2027

United States locations

U.S. sites
18
U.S. states
12
U.S. cities
18
Facility City State ZIP Site status
Retinal Research Institute /ID# 255925 Phoenix Arizona 85053
California Retina Consultants - Bakersfield /ID# 255910 Bakersfield California 93309-1677
Retina Vitreous Assoc Med Grp /ID# 255921 Beverly Hills California 90211
Retinal Diagnostic Center /ID# 272275 Campbell California 95008
Northern California Retina Vitreous Associates Medical Group, Inc /ID# 255920 Mountain View California 94040-4101
Retina Consultants of San Diego /ID# 255911 Poway California 92064-2530
California Retina Consultants - Santa Barbara /ID# 255923 Santa Barbara California 93103
Southeast Retina Center /ID# 255912 Augusta Georgia 30909
Springfield Clinic - First /ID# 272274 Springfield Illinois 62702
Johns Hopkins Hospital /ID# 255919 Baltimore Maryland 21287
Ophthalmic Consultants of Boston /ID# 255917 Boston Massachusetts 02114
Sierra Eye Associates /ID# 255908 Reno Nevada 89502
Eye Associates of New Mexico /ID# 255915 Albuquerque New Mexico 87109
Duke University Medical Center /ID# 267646 Durham North Carolina 27710
Mid Atlantic Retina /ID# 255906 Philadelphia Pennsylvania 19107
Charles Retina Institute /ID# 255922 Germantown Tennessee 38138
Tennessee Retina - Nashville /ID# 255918 Nashville Tennessee 37203-1513
Retina Consultants - The Woodlands /ID# 255924 The Woodlands Texas 77384

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04514653, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04514653 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →